Verve Ventures

Aktiia focuses on continuous and accurate blood pressure monitoring to address the global challenge of hypertension, which affects over 1.4 billion people and contributes to more than 18 million deaths annually. Founded on two decades of research, Aktiia's innovative technology combines optical sensors with clinically validated software algorithms to provide personalized, medical-grade blood pressure and heart rate data. This continuous monitoring enables individuals, researchers, and clinicians to gain deeper insights into hypertension, fostering more effective and personalized patient care. By improving accessibility and accuracy in blood pressure management, Aktiia aims to change the approach to this critical health issue, ultimately enhancing the understanding and treatment of high blood pressure.

Neo aims at transforming the current approach to spinal surgery by providing a unique answer to the worldwide strive for healthcare cost optimization through efficient, versatile and high quality systems.

Limula is a company that has developed an innovative platform technology designed to enhance the scalability of cell therapy production. By integrating a bioreactor and a centrifuge into a single device, Limula's solution enables healthcare providers to manufacture cell and gene therapies in a decentralized manner, bringing these treatments closer to patients. This platform, which includes hardware, software, and consumables, aims to make highly personalized and curative therapies more accessible. The automation of the production process not only increases safety and reproducibility but also allows for the large-scale manufacturing of cell therapy products, thereby addressing the critical need for improved access to gene-engineered therapies.

Artiria Medical SA develops innovative micro-actuated devices aimed at treating vascular diseases, particularly in the brain. Founded in 2019 and based in Lausanne, Switzerland, the company focuses on enhancing the precision and control of surgical procedures involving catheters and guidewires. Its technology facilitates micromotion within brain arteries, thereby improving navigation during stroke treatments. By enabling surgeons to perform these complex procedures with greater accuracy, Artiria Medical contributes to better patient outcomes and the potential to save lives.

Aktiia focuses on continuous and accurate blood pressure monitoring to address the global challenge of hypertension, which affects over 1.4 billion people and contributes to more than 18 million deaths annually. Founded on two decades of research, Aktiia's innovative technology combines optical sensors with clinically validated software algorithms to provide personalized, medical-grade blood pressure and heart rate data. This continuous monitoring enables individuals, researchers, and clinicians to gain deeper insights into hypertension, fostering more effective and personalized patient care. By improving accessibility and accuracy in blood pressure management, Aktiia aims to change the approach to this critical health issue, ultimately enhancing the understanding and treatment of high blood pressure.

MedTrace Pharma A/S, founded in 2015 and based in Kongens Lyngby, Denmark, specializes in the development of innovative solutions for positron emission tomography (PET) imaging. The company has created an automated system, known as MT-100, which efficiently produces and injects 15O-water, a radioactive tracer essential for enhanced imaging. This system is designed to integrate seamlessly with in-house cyclotrons and PET scanners, significantly increasing the sensitivity of patient analysis while improving throughput by up to four times compared to conventional methods. Additionally, MedTrace Pharma develops the aQuant analytical platform, which aids in interpreting PET scan results, further optimizing the diagnostic process. With additional offices in Boston, Massachusetts, and Uppsala, Sweden, MedTrace is focused on advancing the capabilities of clinical imaging through automation and innovative technology.

Hylomorph is a MedTech company that specializes in providing fibrotic encapsulation solutions in implantable medical devices. The company was founded in 2014 and is headquartered in Zurich, Switzerland.

German Version below: marta offers a market place for families, people in need of care and European caregivers. We believe that, on the one hand everyone has the right to receive appropriate care and to age with dignity and on the other hand caregivers should be able to do their work under fair conditions. We are working on software solutions to connect caregivers with families across Europe and we support both parties during the entire process. In our own families we have seen that the current market is characterized by non-transparent services and does not deliver adequate quality. It is out mission to change that. That is why we at marta pursue the goal of making things better by applying our software solutions to fundamentally rebuilding the "24-hour" care market. Deutsche Version: marta bietet einen Marketplatz für Familien, pflegebedürftige Menschen und europäische Pflegekräfte. Aus unserer Sicht, hat zum einen jede/r das Recht darauf, angemessene Pflege zu erhalten und in Würde zu altern und zum anderen sollten Pflegekräfte unter fairen Bedingungen ihre Arbeit machen können. Wir arbeiten an dem Bau von Softwarelösungen, um Pflegekräfte mit Familien in ganz Europa zu verbinden und während der Betreuung zu begleiten. In unseren eigenen Familien haben wir gesehen, dass der derzeitige Markt von intransparenten Dienstleistungen geprägt ist und keine angemessene Qualität liefert. Deswegen verfolgen wir bei marta das Ziel, es durch unsere Softwarelösungen besser zu machen und den Markt der "24-Stunden" Pflege grundlegend neu aufzubauen.

Piomic is a developer of a non-invasive medical device aimed at treating chronic wounds, particularly in patients with hard-to-heal leg and foot ulcers. The company's flagship product, the COMS® One Therapy System, is a portable, hand-held device that uses optical and magnetic stimulation technologies to promote wound healing. Clinical studies demonstrate that this device is safe and effective, leading to accelerated wound closure, reduced pain, and improved quality of life for patients. Designed for ease of use, the device features a single-button operation and can be utilized in various settings, including stationary and ambulatory facilities, as well as in patients’ homes. By focusing on a therapy that provides significant benefits, Piomic seeks to improve the treatment outcomes for individuals suffering from chronic wounds and alleviate the cost burden on healthcare systems.

Sleepiz AG, based in Zurich, Switzerland, specializes in manufacturing a non-contact sleep monitoring device aimed at enhancing healthcare accessibility in home environments. Incorporated in 2018, the company's innovative product is designed to be placed on a bedside table, where it accurately measures patients' breathing patterns, heart rate, and body movements using advanced wireless millimeter wave technology and artificial intelligence. This device not only facilitates the diagnosis of sleep disorders but also enables long-term monitoring of chronic diseases, allowing healthcare providers to track patient progression and implement timely interventions for improved treatment outcomes. Through its user-friendly and precise approach, Sleepiz is positioned to significantly contribute to patient-centric disease management.

9T Labs AG, founded in 2018 and based in Zürich, Switzerland, specializes in manufacturing 3D printers that produce carbon composite parts. The company integrates advanced software, additive manufacturing, and industry-standard materials to offer a digital composite production solution. Utilizing its proprietary Additive Fusion Technology (AFT), 9T Labs enables manufacturers to create lightweight structural components with precise 3D fiber orientation, facilitating mass production at reduced costs. The intuitive design software supports optimal fiber placement, while automated production equipment enhances efficiency across the entire value chain. The technology allows for the efficient production of high-performance parts, including applications in drones and prosthetics, making it accessible for engineers and manufacturers alike.

Nanoleq AG, established in 2017 and based in Zurich, Switzerland, specializes in the development and manufacturing of innovative electric cables using stretchable electronics. As a spinoff from ETH Zurich, the company focuses on integrating electronic functionalities into textiles, particularly for health monitoring. Its products utilize advanced conductive silicone technology to create soft sensors capable of recording vital signs such as heartbeat, electrocardiograms, and breathing patterns through comfortable and washable garments. These sensors are designed for various applications, including healthcare, sports, and workwear, with the aim of setting a standard in the health-monitoring textile market. Nanoleq is committed to facilitating the rapid development and widespread adoption of smart textiles across multiple sectors, including robotics and aerospace.

Hylomorph is a MedTech company that specializes in providing fibrotic encapsulation solutions in implantable medical devices. The company was founded in 2014 and is headquartered in Zurich, Switzerland.

Medimaps Group specializes in developing medical tools that enhance the assessment of bone microarchitecture, particularly for diagnosing and managing osteoporosis. The company's software utilizes artificial intelligence to analyze imaging data from various sources, including DXA, X-ray, and projected CT images, employing techniques such as the trabecular bone score. By providing detailed insights into bone texture, Medimaps Group aids physicians in selecting appropriate treatment options and monitoring patient outcomes. Additionally, the company is exploring future applications of its technology in the dental and orthopedic fields, further expanding its impact on patient care through improved assessment of bone health.

PathoQuest SAS is a biotechnology company that specializes in advanced metagenomics for pathogen detection, having originated as a spin-off from Institut Pasteur. The company utilizes proprietary next-generation sequencing (NGS) technology, which combines innovative sample preparation with a comprehensive database of pathogen genomic information. This approach allows clinicians and biopharmaceutical professionals to enhance the detection of infectious agents in various biological samples. PathoQuest's Viral Safety testing service, aimed at biopharmaceutical companies, represents its first commercial application and has rapidly generated revenue from major industry players. The company's cloud-based bioinformatics platform and automated analysis pipeline further facilitate improved pathogen detection, making its solutions valuable for both clinical and biopharmaceutical quality assurance.

Aktiia focuses on continuous and accurate blood pressure monitoring to address the global challenge of hypertension, which affects over 1.4 billion people and contributes to more than 18 million deaths annually. Founded on two decades of research, Aktiia's innovative technology combines optical sensors with clinically validated software algorithms to provide personalized, medical-grade blood pressure and heart rate data. This continuous monitoring enables individuals, researchers, and clinicians to gain deeper insights into hypertension, fostering more effective and personalized patient care. By improving accessibility and accuracy in blood pressure management, Aktiia aims to change the approach to this critical health issue, ultimately enhancing the understanding and treatment of high blood pressure.

Scewo AG, founded in 2017 and headquartered in Winterthur, Switzerland, specializes in designing and manufacturing innovative electric wheelchairs tailored for individuals with mobility impairments. The company has developed a unique stair-climbing wheelchair that integrates both wheels and tracks, allowing for enhanced maneuverability over various terrains, including curbs, tram tracks, grass, and uneven surfaces. This self-balancing wheelchair features an active control system that maintains stability and levelness, enabling users to navigate obstacles with ease. Users can control the chair through a joystick or by shifting their body weight, providing a versatile solution to improve mobility and independence for those with disabilities.

Sleepiz AG, based in Zurich, Switzerland, specializes in manufacturing a non-contact sleep monitoring device aimed at enhancing healthcare accessibility in home environments. Incorporated in 2018, the company's innovative product is designed to be placed on a bedside table, where it accurately measures patients' breathing patterns, heart rate, and body movements using advanced wireless millimeter wave technology and artificial intelligence. This device not only facilitates the diagnosis of sleep disorders but also enables long-term monitoring of chronic diseases, allowing healthcare providers to track patient progression and implement timely interventions for improved treatment outcomes. Through its user-friendly and precise approach, Sleepiz is positioned to significantly contribute to patient-centric disease management.

Sympatient GmbH is a digital therapeutics company based in Hamburg, Germany, that specializes in virtual reality-based psychotherapy solutions for anxiety disorders. Founded in 2017, the company develops medical virtual reality applications aimed at enhancing mental health, particularly in anxiety and stress management. Its flagship products include Otemi, which helps users manage personal stress through various tasks and exercises, and Invirto, an application that provides therapeutic information and strategies for patients to independently treat their anxiety disorders at home. Sympatient also offers a CE-certified medical device for individuals diagnosed with anxiety disorders. By combining technology with traditional therapy methods, Sympatient aims to make mental health treatment more accessible and personalized for patients worldwide.

Fineheart is a France-based medical device company specializing in innovative technologies for cardiovascular care. It focuses on the development of implantable cardiac devices aimed at treating cardiovascular diseases. The company's flagship product is a novel, wirelessly powered, fully implantable mechanical circulatory support device. This device is designed to optimize cardiac output while preserving the heart's natural contractility, thereby enabling patients to restore normal cardiac function. Fineheart's technology aims to improve the quality of life for heart failure patients, allowing them to return to normal daily activities.

EarlySight start-up company is founded in order to accelerate the development and to bring the technology to clinics.

Artiria Medical SA develops innovative micro-actuated devices aimed at treating vascular diseases, particularly in the brain. Founded in 2019 and based in Lausanne, Switzerland, the company focuses on enhancing the precision and control of surgical procedures involving catheters and guidewires. Its technology facilitates micromotion within brain arteries, thereby improving navigation during stroke treatments. By enabling surgeons to perform these complex procedures with greater accuracy, Artiria Medical contributes to better patient outcomes and the potential to save lives.

Sympatient GmbH is a digital therapeutics company based in Hamburg, Germany, that specializes in virtual reality-based psychotherapy solutions for anxiety disorders. Founded in 2017, the company develops medical virtual reality applications aimed at enhancing mental health, particularly in anxiety and stress management. Its flagship products include Otemi, which helps users manage personal stress through various tasks and exercises, and Invirto, an application that provides therapeutic information and strategies for patients to independently treat their anxiety disorders at home. Sympatient also offers a CE-certified medical device for individuals diagnosed with anxiety disorders. By combining technology with traditional therapy methods, Sympatient aims to make mental health treatment more accessible and personalized for patients worldwide.

Neo aims at transforming the current approach to spinal surgery by providing a unique answer to the worldwide strive for healthcare cost optimization through efficient, versatile and high quality systems.

Pregnolia AG is a Swiss company specializing in the development of diagnostic devices aimed at predicting the risk of premature birth during pregnancy consultations. Founded in 2015 and based in Zurich, the company has created a medical probe that measures the strength and stiffness of the uterine cervix, facilitating early risk detection and enabling preventive interventions to prolong gestation and enhance neonatal health outcomes. Pregnolia's technology supports gynecologists by providing critical information that aids in the management of preterm birth risks, ultimately improving pregnancy care. The company is committed to advancing its device through clinical trials and regulatory processes to ensure its successful implementation in healthcare settings.

Aktiia focuses on continuous and accurate blood pressure monitoring to address the global challenge of hypertension, which affects over 1.4 billion people and contributes to more than 18 million deaths annually. Founded on two decades of research, Aktiia's innovative technology combines optical sensors with clinically validated software algorithms to provide personalized, medical-grade blood pressure and heart rate data. This continuous monitoring enables individuals, researchers, and clinicians to gain deeper insights into hypertension, fostering more effective and personalized patient care. By improving accessibility and accuracy in blood pressure management, Aktiia aims to change the approach to this critical health issue, ultimately enhancing the understanding and treatment of high blood pressure.

OncoDNA is a theranostic and genomic company that specializes in precision medicine for cancer and genetic diseases. Founded by a team with over 60 years of experience in medical diagnostics, the company focuses on providing clinical guidance for the treatment and real-time monitoring of late-stage cancer patients. OncoDNA supports researchers and biopharma companies in navigating the complexities of molecular biology, facilitating research and drug development in oncology. With its commitment to delivering precision medicine, OncoDNA aims to enhance treatment outcomes and improve the management of cancer and genetic disorders.

9T Labs AG, founded in 2018 and based in Zürich, Switzerland, specializes in manufacturing 3D printers that produce carbon composite parts. The company integrates advanced software, additive manufacturing, and industry-standard materials to offer a digital composite production solution. Utilizing its proprietary Additive Fusion Technology (AFT), 9T Labs enables manufacturers to create lightweight structural components with precise 3D fiber orientation, facilitating mass production at reduced costs. The intuitive design software supports optimal fiber placement, while automated production equipment enhances efficiency across the entire value chain. The technology allows for the efficient production of high-performance parts, including applications in drones and prosthetics, making it accessible for engineers and manufacturers alike.

Biograil, founded in 2019 and led by CEO Karsten Lindhardt, specializes in developing a medical device that innovatively replaces traditional injection systems for administering medications. Utilizing an injection molding technique, the device is encapsulated in a standard-sized capsule and employs the body's natural peristaltic forces to deliver biologics directly into the gastrointestinal wall. This approach eliminates the need for mechanical moving components, allowing for a painless and efficient method of drug delivery to patients.

PathoQuest SAS is a biotechnology company that specializes in advanced metagenomics for pathogen detection, having originated as a spin-off from Institut Pasteur. The company utilizes proprietary next-generation sequencing (NGS) technology, which combines innovative sample preparation with a comprehensive database of pathogen genomic information. This approach allows clinicians and biopharmaceutical professionals to enhance the detection of infectious agents in various biological samples. PathoQuest's Viral Safety testing service, aimed at biopharmaceutical companies, represents its first commercial application and has rapidly generated revenue from major industry players. The company's cloud-based bioinformatics platform and automated analysis pipeline further facilitate improved pathogen detection, making its solutions valuable for both clinical and biopharmaceutical quality assurance.

Comphya is a company focused on developing an innovative active implantable medical device aimed at restoring erectile function in patients who do not respond to oral medications. The device offers self-controlled stimulation to the cavernous nerve through a wireless remote control, providing a safe and effective alternative for a significant portion of the male population suffering from erectile dysfunction. By addressing this common medical issue, Comphya seeks to enhance the quality of life for these patients.

Hylomorph is a MedTech company that specializes in providing fibrotic encapsulation solutions in implantable medical devices. The company was founded in 2014 and is headquartered in Zurich, Switzerland.

Abionic SA is a Swiss company specializing in nanotechnology-based diagnostic solutions aimed at enhancing medical diagnosis. Founded in 2010 as a spin-off from the Swiss Federal Institute of Technology Lausanne (EPFL), Abionic has developed the abioSCOPE platform, which enables rapid testing of patients' allergy profiles using just a single drop of blood. This innovative platform includes a reader for nanofluidic sensors and a smartphone application, facilitating both clinical laboratory use and point-of-care testing. Abionic's products are designed to assist healthcare professionals in diagnosing and screening various medical conditions, particularly in the realms of allergy and sepsis. The company is ISO 9001/13485 certified, demonstrating its commitment to quality management in the development and commercialization of in vitro diagnostic devices. With strategic support from various Swiss institutions, Abionic aims to become a significant player in personalized medicine on an international scale. The company is headquartered in Lausanne, Switzerland.

Pregnolia AG is a Swiss company specializing in the development of diagnostic devices aimed at predicting the risk of premature birth during pregnancy consultations. Founded in 2015 and based in Zurich, the company has created a medical probe that measures the strength and stiffness of the uterine cervix, facilitating early risk detection and enabling preventive interventions to prolong gestation and enhance neonatal health outcomes. Pregnolia's technology supports gynecologists by providing critical information that aids in the management of preterm birth risks, ultimately improving pregnancy care. The company is committed to advancing its device through clinical trials and regulatory processes to ensure its successful implementation in healthcare settings.

Medyria AG is a Swiss medical technology company focused on developing innovative sensor-based systems for catheter navigation and sensing in cardiovascular procedures. Founded in 2012 and based in Winterthur, Switzerland, Medyria engineers devices that enhance the safety and effectiveness of endovascular surgeries. Its product lineup includes a catheter positioning system that eliminates the need for X-rays and contrast dyes, a blood flow measurement system known as Flowcath, and the Trackcath technology, which processes flow data to facilitate catheter tracking. These technologies aim to streamline minimally invasive procedures, reduce potential complications, and lower overall treatment costs, thereby supporting healthcare professionals in delivering optimal patient care. Medyria operates with a commitment to advancing medical devices that prioritize patient safety and procedural efficiency.

DBS System is a Swiss medtech company specializing in innovative blood collection devices, particularly the HemaXis™ platform. This advanced technology facilitates less invasive and more efficient blood sample collection and preparation, utilizing patented microfluidic technology for plasma and serum extraction with precise volume control. The HemaXis platform aims to enhance the bioanalysis potential of dried blood spot samples, promoting safer and cost-effective practices in medical testing. By streamlining blood collection, DBS System supports the integration of laboratory capabilities into personal health monitoring, ultimately contributing to the advancement of personalized medicine and big data initiatives. The company operates within the Swiss Health Valley, driving innovation in the healthcare sector.

Domo Health is a Swiss company transforming healthcare through its innovative digital health platform that connects patients to their local care environment. Powered by real-world data and AI, we enhance personalized and preventive care at home. With our SaaS clinical platform, domo.health, we monitor patients' conditions, offer safety solutions, and empower professionals to make informed decisions. Together, we're shaping a future focused on safer and healthier in-home experiences.

Domo Health is a Swiss company transforming healthcare through its innovative digital health platform that connects patients to their local care environment. Powered by real-world data and AI, we enhance personalized and preventive care at home. With our SaaS clinical platform, domo.health, we monitor patients' conditions, offer safety solutions, and empower professionals to make informed decisions. Together, we're shaping a future focused on safer and healthier in-home experiences.

Medyria AG is a Swiss medical technology company focused on developing innovative sensor-based systems for catheter navigation and sensing in cardiovascular procedures. Founded in 2012 and based in Winterthur, Switzerland, Medyria engineers devices that enhance the safety and effectiveness of endovascular surgeries. Its product lineup includes a catheter positioning system that eliminates the need for X-rays and contrast dyes, a blood flow measurement system known as Flowcath, and the Trackcath technology, which processes flow data to facilitate catheter tracking. These technologies aim to streamline minimally invasive procedures, reduce potential complications, and lower overall treatment costs, thereby supporting healthcare professionals in delivering optimal patient care. Medyria operates with a commitment to advancing medical devices that prioritize patient safety and procedural efficiency.

Tecuro is a Switzerland-based start-up focused on addressing common issues in urology, particularly urinary tract infections (UTIs). Headquartered in Gerliswil, Luzern, the company has developed an innovative technology platform that provides antimicrobial properties while remaining gentle on the skin. This advancement is especially significant for women's urology, as it offers a means to prevent recurring UTIs through a non-invasive external application, with no known side effects. The company's flagship product, the U-med Pad, is designed for the prevention of urinary tract diseases and is close to market readiness. Tecuro's technology is protected by patents, ensuring a competitive edge and paving the way for future products targeting UTIs and uro-vaginal infections. By introducing this new technology, Tecuro also contributes to the fight against growing antibiotic resistance. The company has successfully completed the necessary steps for scalable production, positioning itself for future growth in the medical technology sector.

Naviswiss develops and commercializes handheld, miniaturized surgical measuring, tracking, and navigation systems. The company’s products include CLIPON, a 3D measurement, and navigation system; LOCAS, a handheld measurement, and navigation system; and NAVITAGS, a marker used to measure the position of the item in space. Its products are primarily used for orthopedic replacement operations, such as hip and knee replacements. Naviswiss provides miniaturized surgical navigation for orthopedic surgeons to accurately implant artificial joints. The company was founded in 2007 and is based in Laufen, Switzerland.

Domo Health is a Swiss company transforming healthcare through its innovative digital health platform that connects patients to their local care environment. Powered by real-world data and AI, we enhance personalized and preventive care at home. With our SaaS clinical platform, domo.health, we monitor patients' conditions, offer safety solutions, and empower professionals to make informed decisions. Together, we're shaping a future focused on safer and healthier in-home experiences.

MEDUDEM Corp. is a company in the digital health sector that focuses on the improvement of collaboration and interaction of all participants involved around chronic diseases (CCM). On the basis of its readily available web- and mobile-based solutions Care Integrator® and Healthbrain®, MEDUDEM Corp. improves collaboration and exchanges between medical professionals and patients, as well as third-party organizations. This provides clear advantages and synergetic benefits for all parties in and around the healthcare market and ensures the interaction and communication in a simple, fast and comprehensive way and manner.

Qvanteq is a medtech startup company, developing novel bioactive stents to address and overcome the clinical adverse effects of today’s available coronary and endovascular stents. Its bioactive Qstent controls in-growth therefore reducing the risk of restenosis and thrombosis. The company was awarded with the CTI start-up label in 2012. Qvanteq was founded in 2009 and is held by private investors. The ISO 13485 certified company is based in Zürich, Switzerland. It is a spin-off company from the Swiss Federal Institute of Technology, Zurich.